Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01865617
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:38.374217+00:00
Published At
2022-05-25T00:00:00+00:00
Record Updated At
2022-05-25
Results Posted At
2022-05-25
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["CD19-Positive Neoplastic Cells Present", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Small Lymphocytic Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-05-25"
protocolSection.identificationModule.nctId
"NCT01865617"
protocolSection.identificationModule.officialTitle
"Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2022-05-25"

Study condition terms

  • CD19-Positive Neoplastic Cells Present (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.